An efficient urine peptidomics workflow identifies chemically defined dietary gluten peptides from patients with celiac disease

Brad A. Palanski[1,13], Nielson Weng[1,2,3,], Lichao Zhang[4], Andrew J. Hilmer[1], Lalla A. Fall[5], Kavya Swaminathan[6], Bana Jabri[7,8,9], Carolina Sousa[10], Nielsen Q. Fernandez-Becker[11], Chaitan Khosla[,1,5,12], and Joshua E. Elias[4]

[1]Department of Chemistry, Stanford University, Stanford, CA, USA. [2]School of Medicine, Stanford University, Stanford, CA, USA. [3]Medical Scientist Training Program, Stanford University, Stanford, CA, USA. [4]Chan Zuckerberg Biohub, San Francisco, CA, USA. [5]Stanford ChEM-H, Stanford University, Stanford, CA, USA. [6]Division of Blood and Bone Marrow Transplantation, Stanford University, Stanford, CA, USA. [7]Department of Medicine, University of Chicago, Chicago, IL, USA. [8]Committee on Immunology, University of Chicago, Chicago, IL, USA. [9]Department of Pathology and Pediatrics, University of Chicago, Chicago, IL, USA. [10]Facultad de Farmacia, Departamento de Microbiología y Parasitología, Universidad de Sevilla, Sevilla, Spain.
[11]Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford, CA, USA. [12]Department of Chemical Engineering, Stanford University, Stanford, CA, USA. [13]Present address: Department of Medicine, Brigham and Women's Hospital, and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA

These authors contributed equally: Brad A. Palanski, Nielson Weng.

These authors jointly supervised this work: Chaitan Khosla, Joshua E. Elias. Email: khosla@stanford.edu, josh.elias@czbiohub.org.

ABSTRACT

Celiac disease (CeD) is an autoimmune disorder induced by consuming gluten proteins from wheat, barley, and rye. Glutens resist gastrointestinal proteolysis, resulting in peptides that elicit inflammation in patients with CeD. Despite well-established connections between glutens and CeD, chemically defined, bioavailable peptides produced from dietary proteins have never been identified from humans in an unbiased manner. This is largely attributable to technical challenges, impeding our knowledge of potentially diverse peptide species that encounter the immune system. Here, we developed a novel liquid chromatographic-mass spectrometric workflow for untargeted sequence analysis of the urinary peptidome. We detected 679 distinct dietary peptides, of which ~35% have a CeD-relevant T cell epitope and ~5% are known to stimulate innate immune responses. Remarkably, gluten peptides from patients with CeD qualitatively and quantitatively differ from controls. Our results provide a new foundation for understanding gluten immunogenicity, improving CeD management, and characterizing the dietary and urinary peptidomes.

INTRODUCTION

In humans, the prevailing understanding of physiological digestion is that proteins are broken down into single amino acids or di- or tri-peptides before absorption as nutrients[1,2]. Gluten proteins found in wheat, barley, and rye are exceptions to this tenet with notable health consequences. Unusual biochemical properties of these proteins, such as a high abundance of glutamine (Gln, Q) and proline (Pro, P) residues, render them resistant to degradation by gastrointestinal proteases[3]. Consequently, relatively long gluten peptides with intact immunotoxic epitopes accumulate in the lumen of the small intestine[4] and cross the epithelial barrier, although the mechanism(s) of transport remain controversial[5]. In approximately 1 in 100 individuals, an aberrant immune response to these peptides causes celiac disease (CeD), an autoimmune disorder that causes small intestinal mucosal injury characterized by villous atrophy. Common symptoms include abdominal pain, bloating, nausea, vomiting and/or diarrhea[6]. Extraintestinal CeD manifestations also occur, including blistering skin rashes and ataxia[7]. At present, the only effective CeD treatment is a strict, lifelong adherence to a gluten-free diet (GFD)[8].

Assays to probe gluten immunogenicity in CeD have typically relied on extracted or recombinant glutens that are digested *in vitro* with gastrointestinal proteases. The resulting peptides can be used in bioassays to characterize mechanisms of immunotoxicity[3]. In most cases, these peptides elicit adaptive immune responses mediated by HLA-DQ2 or -DQ8 antigen presentation to Th1 cells in the small intestinal mucosa of patients with CeD[4,9–14]. Gluten peptides with alternative (i.e., non-T cell-dependent) modes of action have also been reported[15–21]. Structure-function analyses using synthetic gluten peptides have revealed exquisite sequence specificity for both the HLA and T cell receptor; single amino acid alterations can result in dramatically altered affinities, thereby altering the strength of the immune response[22–24].

Although it is well established that chemical variation in gluten peptides can influence CeD immune responses, measuring their naturally processed forms and connecting them with CeD patients' health status is an underexplored research area. Over 20 years ago, chromatographic analysis coupled to UV detection implied the existence of gluten-derived peptides in the urine of patients with CeD[25]. This was confirmed more recently by antibody-based methods[26–29]. Indeed, most current gluten detection methods rely on monoclonal antibodies, which recognize amino acid motifs present in a subset of gluten proteins[30]. Notwithstanding the valuable knowledge that has been gained from analyzing biospecimens with these immunoreagents, they are neither capable of revealing the exact gluten peptide sequences that are present, nor are they comprehensive in that some CeD-relevant peptides may lack the epitopes these antibodies recognize.

To address mounting evidence that many disease-relevant gluten peptides remain to be discovered[31], new methods are needed to recover and precisely characterize *in vivo* gluten digestion products in an untargeted fashion. In fact, not a single chemically defined peptide from wheat (or, to our knowledge, from any dietary protein) has ever been identified from the human circulatory or excretory systems. Consequently, very little is known about the physiological absorption, distribution, metabolism, and excretion (ADME) of gluten. Specifically, we lack insight into the chemical structures of peptides formed from *in vivo* digestion that may stimulate the immune system.

As a step toward filling this knowledge gap, we sought to analyze human urine by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Currently, LC-MS/MS is the most widely used technique for peptide sequencing in complex biological samples. However, many established LC-MS/MS methods suffer from technical limitations when applied to urinary peptidome analysis. High concentrations of urinary salts and metabolites, which are

not efficiently removed by standard reversed-phase or liquid-liquid extraction procedures, can overwhelm chromatography systems and interfere with peptide detection[32,33]. Here, we develop a novel sample preparation and LC-MS/MS method that utilizes mixed cation exchange solid phase extraction to exclude these interfering molecules in a single step. This workflow overcomes problems we initially encountered with adapting established methods for urinary peptidomics, such as the need for time-consuming strong cation exchange purification and/or limited depth of peptide sampling. With it, we can now efficiently identify dietary gluten peptides and report the precise sequences of such peptides in the urine of human volunteers. We also undertake an exploratory clinical study, which revealed wheat-derived peptides that are substantially different in their chemical and biological properties and are differentially found in patients with CeD versus healthy controls. These peptides are attractive candidates for improving CeD diagnosis and for monitoring patient compliance to gluten-free diets. They also set the stage for elucidating mechanisms underlying the anomalous ADME characteristics of gluten and other dietary proteins. More generally, the successful application of our urinary peptidomic workflow to CeD suggests it should be broadly applicable for direct measurement of any endogenous or exogenous peptide present in urine.

RESULTS

LC-MS/MS Method Development

Previous chromatographic and antibody-based detection methods suggested the presence of gluten-derived peptides in human urine but were incapable of directly elucidating their sequences[25–29]. To determine if an unbiased LC-MS/MS approach could be used for this purpose, we initially analyzed urine samples from volunteers who had consumed a meal rich in dietary gluten by following an extraction and analysis protocol typically used in LC-MS/MS-based proteomics studies (**Supplementary Methods**). These exploratory efforts yielded just one gluten-derived peptide identification. Furthermore, very few endogenous human peptides were detected (**Supplementary Fig. 1**). In accordance with challenges previously reported with urinary peptidome experiments[32,33], we noted severe degradation of the LC column and MS electrospray source over consecutive analyses, preventing us from analyzing multiple samples without unacceptable interruptions in instrument operation.

We therefore endeavored to systematically optimize each step in our peptidome extraction and LC-MS/MS analytical protocols in order to reliably detect peptides from urine. Starting with urine from an individual challenged with dietary gluten, we first confirmed it had measurable gluten levels by ELISA. The commercially available R5 monoclonal antibody we used targets the pentameric motif QXP(W/F)P found in many gluten proteins[34] and is therefore expected to react with gluten peptides produced by patients with CeD and healthy controls. Using this reference specimen, we tested a variety of methods to enrich and purify urinary peptides. In addition, we optimized the LC gradient and MS acquisition method (**Supplementary Methods**). These efforts resulted in >30- and >12-fold increases in the number of identifiable wheat- and human-derived peptides, respectively, while eliminating longstanding problems with instrument contamination by background metabolites (**Supplementary Methods, Supplementary Figs. 2-3,** see also Method Specificity section below). Importantly, by combining solid-phase extraction on a mixed-cation exchange column with online reversed-phase LC and high-resolution MS/MS analysis, this workflow shortened our sample preparation time from 2-3 days to 6 hours (**Fig. 1**). This allowed sufficient throughput for us to undertake comparative analysis of clinical urine samples.

Pilot Identification of Chemically Defined Urinary Wheat Peptides

To evaluate our optimized urine peptidome extraction and LC-MS/MS method, four healthy participants were recruited into a pilot study outlined as follows (**Fig. 2a**): On the first day, participants initiated a GFD. The GFD was maintained on the second day, and a pooled urine sample was collected over 8 h. On the third day, participants underwent a gluten challenge comprised of two wheat bagels (~18 g gluten), and subsequently collected a second pooled urine specimen over the next 8 h. LC-MS/MS analysis of these urine samples yielded an average of 24 unique peptide sequences per participant mapping to the wheat proteome, all of which were identified only in the post-gluten challenge samples (**Supplementary Dataset 3**). The number of unique wheat peptides varied widely between individual volunteers (**Fig. 2b**). In contrast, the number of detected human peptides was essentially unchanged in the GFD versus post-challenge samples (**Supplementary Fig. 4**).

In anticipation of recruiting larger cohorts of human participants, we sought to confirm our initial findings while also simplifying the dietary gluten challenge protocol. The four original participants, along with four additional healthy participants, were asked to fast overnight in place of the 48 h GFD employed in the pilot study (**Fig. 2c**). Then, a single urine sample was collected before consumption of two wheat bagels for breakfast and collection of a pooled 8 h urine sample. Wheat peptides were readily detected in all post-challenge samples (**Fig. 2d and Supplementary Table 2**), while the number of human peptides was similar in both sample groups (**Supplementary Fig. 5**). These results support our initial finding that a dietary gluten challenge consistently leads to urinary gluten peptides that are measurable by LC-MS/MS. They also indicate that levels of these peptides fall to undetectable levels after overnight fasting, justifying use of the abbreviated protocol for subsequent studies.

Considering all sequences of the wheat-derived peptides identified from healthy participants (**Supplementary Datasets 3 and 4**), four noteworthy characteristics were apparent (**Fig. 2e**). First, although 125 unique peptide sequences were identified, only one peptide was found in common in all 8 participants: GQQQPFPPQQPYPQPQPFPS. Its C-terminally truncated derivative, GQQQPFPPQQPYPQPQPFP, was identified in 7/8 participants; other overlapping variants of these peptides were also detected in more than one urine sample. While these sequences from α-gliadin proteins are not known to be recognized by patient-derived T cells, multiple studies have demonstrated that they can stimulate an innate immune response[15–21]. Strikingly, these prevalent urinary peptides do not have a motif that is recognized by monoclonal antibodies commonly used for gluten detection[34,35]. Thus, they would evade detection by traditional immunoassays.

Second, we identified many peptides harboring known CeD-relevant T cell epitopes[36]. The DQ2.5-glia-γ4c/DQ8-glia-γ1a epitope was most common, with 32 distinct peptides harboring the corresponding QQPQQPFPQ sequence. The DQ2.5-glia-γ5 epitope (QQPFPQQPQ) also appeared frequently, as it was identified in 14 unique peptides. Other known T cell epitopes, including DQ2.5-glia-γ1 (PQQSFPQQQ), DQ2.5-glia-γ3 (QQPQQPYPQ), and DQ2.5/2.2-glut-L1 (PFSQQQQPV) were identified less frequently (**Supplementary Table 1**)**.** Some T-cell stimulatory peptides, such as FLQPQQPFPQQPQQPYPQQPQQPFPQ and SQQPQQPFPQPQQQFPQPQQPQ, harbor more than one epitope and were previously identified as being both proteolytically resistant and highly inflammatory to CeD patients through *in silico* and *in vitro* analysis[37].

Third, some peptides such as PyrQTFPHQPQQQVPQPQQPQQP had undergone post-translational modification via cyclization of an N-terminal Gln into a pyroglutamic acid residue. The possibility that this modification occurs during sample processing cannot be excluded. However, N-terminal pyroglutamination is known to protect peptides from proteolytic degradation[38–40] and thus may contribute to their stability in circulation.

Last, we found novel gluten peptides from human urine that have not been described by any prior study as either being resistant to gastrointestinal digestion or as having any

pathophysiological characteristics. One such peptide, SCHVMQQQCC, is derived from γ-gliadin and from the low molecular weight subunits of glutenins B and C. It was identified in 6/8 participants, while its C-terminally truncated form was detected in 5/8 urine samples. Longer and shorter versions were also detected in multiple samples. This result illustrates the power our untargeted approach has for identifying wheat-derived peptides that have eluded prior description despite their seemingly common representation.

Method Specificity

To our knowledge, the above proof-of-concept studies report the first untargeted detection of diet-derived peptides in humans. We therefore sought to confirm that our LC-MS/MS method reliably detects these peptides and accurately identifies their sequences in the complex background of the human urinary peptidome. To do so, we took advantage of the fact that rye and barley also contain proteolytically resistant gluten proteins[41]. For example, wheat gliadins (one of two major protein families that comprise gluten) are homologous to secalin proteins in rye and hordeins in barley (**Fig. 3a**). We thus anticipated that urine analysis should distinguish the particular grain consumed by volunteers who ate meals rich in either wheat, barley, or rye. To test this hypothesis, two healthy participants fasted overnight, and then, on different days, maintained a grain-free diet, or ate breakfasts prepared with approximately 1.5 cups of wheat, barley, or rye flour. Urine was then collected for 8 h, analyzed by our optimized LC-MS/MS protocol, and the data were searched against a customized database that included the human, rye, wheat, and barley proteomes (**Supplementary Methods**).

When participants maintained a grain-free diet, only a single grain peptide (likely a false discovery) was identified. In contrast, subsequent to wheat, rye, and barley dietary challenges, we respectively detected 51, 43, and 37 unique grain peptide sequences (**Supplementary Dataset 5).** The human peptide repertoire was similar in all specimens (**Supplementary Fig. 6**). Notably, all identified peptides were restricted to just one dietary challenge (**Fig. 3b**), suggesting that our method readily differentiates peptides formed from different dietary proteins. Indeed, when the sequences were mapped onto the grain proteomes, the majority were predominately derived from the corresponding dietary challenge (**Fig. 3c and Supplementary Fig. 7**). We attribute the fact that fewer sequences could be mapped to the rye proteome from rye challenge urine as a likely artifact of the small size of the rye proteome available from the UniProt resource, which contains ~100x fewer sequences than the wheat or barley proteomes, despite their genomes having similar sizes. Our data suggest that many of the detected sequences in the rye challenge urine may be derived from yet unannotated rye proteins whose sequences are also present in the wheat proteome. Taken together, these results demonstrate that the peptides detected by our method originate from the diet. They also confirm the specificity of our method to distinguish closely related dietary components.

Preliminary Analysis of Banked Urine from Patients with CeD

To test our ability to identify wheat-derived peptides in the urine of individuals with CeD, we analyzed a set of nine urine samples banked from a prior study[27]. These urine samples were collected from single voids of patients with confirmed CeD diagnoses and were previously assayed for gluten presence by lateral flow immunoassay. This immunoassay used G12 and A1 monoclonal antibodies, which specifically recognize the pentameric amino acid motifs QPQLP(Y/F) and QLP(Y/F)PQP, respectively[35]. Samples (n=4) from patients reporting adherence to a GFD and in which the measured gluten peptide concentrations were below the lateral flow assay limit of quantification were analyzed as negative controls. In accordance with the lateral flow results, we did not measure peptides mapping to the wheat proteome by LC-MS/MS. In contrast, all samples (n=5) for which lateral flow assays indicated high apparent gluten peptide concentrations, yielded at least 16 wheat peptide sequences (**Fig. 4**) by LC-

MS/MS. The mean number of identified wheat peptides (74 per sample) was much higher than those described in our proof-of-concept studies with healthy participants (24 per sample; **Fig. 2b,d**) while the number of human peptides was similar (**Supplementary Fig. 8**). Strikingly, one sample from a patient with CeD yielded 206 distinct wheat peptides, a quantity four times greater than in any healthy participant analyzed previously. These intriguing observations led us to hypothesize that the urinary wheat peptide repertoires of patients with CeD are much more diverse than non-CeD individuals. We therefore initiated a prospective clinical study to formally test this hypothesis, described below.

Clinical Study

Adult patients with gastrointestinal symptoms including dyspepsia, bloating and diarrhea who were eating gluten-containing diets and were undergoing evaluation for CeD were recruited within the Celiac Disease Program at the Stanford Digestive Health Center, along with gender-matched healthy controls (**Fig. 5a**). CeD vs. non-CeD diagnoses were not known at the time of enrollment and were subsequently established by serology and endoscopy with biopsy. All participants undertook a dietary gluten challenge and urine collection according to the optimized study design depicted in **Fig. 2c**. At the end of the recruitment period, urine samples were processed and analyzed by LC-MS/MS. Compared to healthy controls (n=8) and patients ultimately diagnosed with non-celiac gastrointestinal disorders (n=5), patients with CeD (n=6) had 2.5-fold more unique gluten peptides in their urine (**Fig. 5b**), while the number of endogenous human peptides was similar in all three groups **(Supplementary Fig. 9**)**.**

Consistent with our pilot studies, variants of the innate immune response stimulating-peptide GQQQPFPPQQPYPQPQPFPS were detected in all individuals, regardless of clinical status (**Supplementary Dataset 7**). We analyzed whether patients with CeD had increased diversity of peptides with T cell epitopes known to stimulate the adaptive immune response. Indeed, the number of peptides with at least one CeD-relevant T-cell epitope was approximately 4-fold higher in patients with CeD **(Fig. 5c,d**). All CeD-relevant T cell epitopes occurred more frequently in participants with CeD, and seven different T cell epitopes completely absent in controls were found in patients (**Fig. 5d and Supplementary Table 2**). Overall, we measured 289 unique wheat peptides from patients with CeD that were not detected in healthy individuals or patients with non-celiac gastrointestinal disorders, whereas only 36 peptides were shared between all three groups (**Fig. 5e and Supplementary Dataset 7)**.

To gain insight into the diversity of peptide sequences found in patients with CeD, we ranked the frequency by which CeD-specific peptide sequences were detected (**Supplementary Dataset 8**). Just four peptides were found in the majority of (≥4/6) patients (**Fig. 5f**), whereas most (207) were detected only in single individuals. To understand the chemical space occupied by the peptides that were found in patients with CeD, we aligned the detected peptide sequences to the wheat proteome (**Fig. 5g-h**). Strikingly, patients with CeD not only had more variants (i.e., slightly longer or shorter versions) of peptides found in controls, but they also possessed peptides that mapped to distinct regions of the wheat proteome (**Supplementary Fig. 10**). For example, three patients had peptides spanning residues 194-199 of γ-gliadin (GDBX) that were absent in controls (**Fig. 5g**). Taken together, these results demonstrate that patients with CeD have peptidomes that are more diverse in their chemical and biological properties compared to control participants.

DISCUSSION

Despite extensive research into the mechanisms by which gluten proteins play a role in CeD pathogenesis (**Fig. 6**), the identities of the actual diet-derived molecules that interact with the human immune system in the gut and other organs have been a long-standing mystery. As a step toward illuminating these molecular interactions, we developed a novel LC-MS/MS-based

assay that directly detects the metabolic products of food grains. In contrast to *in vitro* gluten preparations that have been standard research tools in the CeD field for several decades, our method is compatible with *in vivo* dietary challenge. It therefore can reveal, for the first time, the precise chemical structures of dietary peptides that may drive CeD in humans. Furthermore, unlike traditional antibody reagents, the untargeted LC-MS/MS readout readily distinguishes the precise amino acid sequences of digestion-resistant peptides from wheat, barley, and rye. Thus, this method provides a unique window into gluten's ADME characteristics and immunogenicity. Indeed, we observed more varied wheat peptide repertoires from patients with CeD than was previously appreciated – and ones that were much more diverse than those found in non-CeD individuals.

Initially, our efforts were hindered by LC-MS/MS methods that were unsuited to the unique challenges of urinary peptidome analysis. Urine contains high concentrations of metabolites and salts that are difficult to separate from peptides and are incompatible with LC-MS/MS[32,33]. Therefore, we developed an extraction technique to remove these interfering compounds (**Supplementary Fig. 3**), and dramatically improve our ability to measure all urinary peptides, including those derived from wheat. Our workflow (**Fig. 1**) is compatible with standard reversed-phase LC-MS/MS instrumentation available in most proteomics laboratories[42]. It is less time- and labor-intensive than prior approaches, while also allowing the identification of 2-to-10-fold more endogenous human peptides from typical 1-10 mL urine samples[32,33,43,44]. This methodological advance allowed us to undertake a comparative analysis of the wheat-derived urinary peptidomes of patients with CeD and healthy controls. Given its high specificity (**Fig. 3**), our workflow should be readily applicable to other studies requiring analysis of the urinary peptidome. Although here we focused on identification of wheat derived peptides, we also identified over 30,000 human peptides (**Supplementary Datasets 1-7**), which is to our knowledge, is the largest collection of urinary peptides sequenced by LC-MS/MS to date. Moreover, we have deposited the raw data in the PRIDE database to allow additional analyses (e.g., using other variable modifications or alternative search engines).

This study is the first to identify the specific amino acid sequences and post-translational modifications of the peptides resulting from *in vivo* digestion of gluten or any other dietary protein. In our pilot identification of dietary wheat peptides in healthy participants (**Fig. 2**), we identified sequences with known CeD relevance, as well as others that had never been implicated in CeD or identified as being resistant to gastrointestinal digestion. These findings underscored the value of our untargeted LC-MS/MS method and motivated us to analyze the urine of patients with CeD.

Using banked urine specimens, we found that wheat-consuming patients with CeD had substantially greater gluten peptide diversity than non-CeD individuals (**Figs. 2 and 4**). We confirmed this finding with a subsequent controlled clinical study (**Fig. 5**) in which participants followed our well-defined gluten challenge protocol (**Fig. 2d**). Mechanistically, this peptide diversity may stem from the fact that individuals with active CeD have elevated intestinal permeability, which likely allows wheat-derived peptides to more readily cross the epithelial barrier[5]. This phenomenon could lead to increased peptide concentrations in the systemic circulation and in urine, thereby enhancing their ability to be detected. A different (or complementary) explanation is that patients with CeD digest and/or metabolize wheat differently than other individuals. Such potential differences in wheat metabolism could contribute to the onset of CeD. Future analyses of patients with other non-CeD enteropathies known to cause "leaky gut" such as tropical sprue as well as disorders in which the mucosa remains grossly intact such as irritable bowel syndrome with diarrhea should be insightful in pinpointing the origins the increased peptide diversity observed in patients with CeD[45,46]. More fundamentally, analysis of urine from individuals consuming diets with various food additives, such as microbial transglutaminase, should help to address the emerging hypothesis that these additives contain

increased levels of immunogenic peptides and/or directly contribute to increases in intestinal permeability[47,48].

We identified 18 distinct immunotoxic epitopes known to be presented on MHC class II molecules and recognized by T-cells that reside in the lamina propria of patients with CeD. Many of these epitopes occurred more frequently in patients with CeD than in controls (**Fig. 5d**). Notably, however, we were unable to detect in its intact form an extensively studied and highly inflammatory 33-residue peptide from α2-gliadin that accumulates in the mammalian gut lumen under physiological conditions by virtue of its resistance to gastrointestinal proteolysis[4]. Its apparent absence from human urine could be due to physicochemical properties that hinder absorption, promote systemic metabolism, or make it unamenable to chemical extraction and/or detection by mass spectrometry. Nonetheless, it is just as noteworthy that an analogous 26-residue peptide from γ-gliadin, FLQPQQPFPQQPQQPYPQQPQQPFPQ, was observed in 2/7 patients with CeD. This peptide is also proteolytically resistant and highly inflammatory to CeD-specific T cells on account of its polyvalency[37].

Despite the abundance of immunogenic wheat peptides in urine, thus far we have been unable to definitively identify any peptide that underwent regioselective Gln deamidation by transglutaminase 2 (TG2), an important step in CeD pathogenesis (**Fig. 6**). Because TG2-catalyzed deamidation increases the immunogenicity of gluten-derived peptides by several orders of magnitude[4], it is possible that a relatively small molar fraction of absorbed gluten is deamidated in patients with CeD, making the concentrations of these peptide species too low to be detectable. Alternatively (or additionally), deamidation may enhance the metabolic lability of circulating gluten peptides. The possibility that their high affinity for HLA-DQ2 or -DQ8 alters their ADME characteristics should not be overlooked. Regardless, future development of targeted LC-MS/MS methods could facilitate detection of low-abundance deamidated gluten peptides.

There is increasing interest in non-invasive monitoring of GFD compliance via urinalysis[26–28,49], as a large proportion of patients with CeD experience symptoms even when attempting to adhere to a GFD[50]. Available methods predominantly exploit the G12 monoclonal antibody, which preferentially recognizes the immunotoxic QPQLP(Y/F) motif found in several CeD-relevant T-cell epitopes[35]. Our data suggest that this motif is rare in urine from individuals who consume dietary wheat (**Fig. 5e**). In contrast, the sequence GQQQPFPPQQPYPQPQPFPS appeared in the urine of every gluten-challenged individual in this study regardless of CeD status. Most urine samples also contained longer or shorter variants of this sequence. Interestingly, a variant of this peptide has been widely investigated for its ability to actuate the innate immune response by stimulating production of IL-15[17–21], a key cytokine in CeD pathogenesis[51,52]. At a minimum, our findings suggest that antibody-based detection methods for monitoring GFD compliance could be vastly improved by targeting detection of this common urinary peptide.

The results reported here pave the way for designing improved diagnostic methods for CeD. Although we observed a statistically significant increase in the number of wheat-derived peptides in patients with CeD compared to healthy controls and individuals with other gastrointestinal aliments, the range of unique peptide sequences was quite broad, suggesting that peptide number alone is unlikely to be sufficiently sensitive or selective for CeD diagnosis. Only a small subset (~2%) of 289 CeD-unique peptides occurred in the majority of patients, while ~75% of these sequences were uniquely detected in single individuals (**Supplementary Dataset 8).** This broad distribution of detected peptide sequences likely stems from the intrinsically high variability of protein digestion[53], as well as the fact that CeD is a highly heterogenous disease in terms of symptoms and extent of gastrointestinal damage[54]. Nonetheless, a subset of diet-derived peptide sequences tended to occur more frequently in CeD patients (**Fig. 5h and Supplementary Dataset 8**). Undoubtedly, future studies using larger sample cohorts will be required to identify and validate strong candidate peptides for diagnostic

purposes. Such validation studies should benefit from development of targeted LC-MS/MS methods that reproducibly sample and quantify the peptides of interest.

Beyond monitoring and diagnosing CeD, our urine peptidomic workflow has potential to advance our fundamental understanding of gluten immunogenicity. Recent evidence indicates that only half of gluten-reactive T cells recognize a known epitope[31]. Analysis of urine from gluten-challenged individuals with T-cells of unknown sequence specificity may reveal candidate epitopes that can be tested in immunoassays. Knowledge of the complete repertoire of disease-relevant wheat peptide sequences that encounter the immune system *in vivo* will be critical to advance efforts to treat CeD by sequestering, degrading, or blocking the interaction of these peptides with immune cells[8].

Generally, our sample extraction and LC-MS/MS analysis protocol promises to reveal new biological insights currently hidden in the urinary peptidome. For example, there is longstanding interest in bioactive peptides derived from dietary proteins other than gluten, but little direct evidence for their existence in humans[2]. More broadly, while it is appreciated that urinary peptides may reflect an individual's health status, few peptides have been identified as disease biomarkers[55]. The high specificity and throughput afforded by our urinary peptidomics workflow should enable investigations into questions such as these that require identification of the sequences and post-translational modifications of exogenous or endogenous urinary peptides.

METHODS

Human Urine Donors. Control urine samples were obtained from healthy adult volunteers without any gastrointestinal symptoms suggestive of CeD. Urine samples were also obtained from eleven adult participants undergoing evaluation for suspected CeD within the Celiac Disease Program at the Stanford Digestive Health Center, in accordance with a protocol approved by the Stanford institutional review board (#20362). Subsequent to urine collection, six of these individuals were diagnosed with CeD on the basis of abnormally high anti-TG2 and deamidated gliadin peptide antibody titers and a confirmatory endoscopy with biopsies demonstrating villous atrophy, in accordance with currently accepted diagnostic guidelines[56]. Five individuals were determined to have non-celiac gastrointestinal ailments on the basis of negative anti-TG2 and deamidated gliadin peptide antibody titers, and optically and histologically normal small bowel on endoscopy (with the exception of one patient who refused endoscopy). All participants provided informed consent, and ethical approval for these sample collections was obtained from the Institutional Review Board for Human Subject Research of Stanford University (Stanford, CA). Urine samples from participants analyzed in Fig. 5 frozen on the day of collection and stored until the end of the two-year study recruitment period. All samples were then defrosted and processed on the same day, as detailed below. Further details related to these participants are provided in **Supplementary Table 3**. The data in **Fig. 4** were obtained from analysis of banked urine samples of individuals with a confirmed CeD diagnosis from a previously published study[27]. Participants provided informed consent, and the local ethics committee of the Hospital Universitario Virgen del Rocío (Sevilla, Spain) approved the study.

Urine Conditioning and Immunochromatographic Test for Detection of Gluten Immunogenic Peptides. Urine samples were processed according to the manufacturer's recommendations (iVYCHECK GIP Urine, Biomedal S.L., Seville, Spain), and subsequent to the processing of the sample: 100 µL of the sample was added onto the detection test strip. After 30 min, the immunochromatographic strip was measured in the cassette of the lateral flow test reader, essentially as previously described[29].

Gluten Challenge and Urine Collection. In initial experiments, participants followed a gluten-free diet for one day, and then continued the gluten-free diet and collected a pooled urine sample for 8 h on the second day, beginning with the second morning void. On the third day, volunteers underwent a dietary gluten challenge consisting of two bagels made with wheat flour (approximately 9 g gluten each). After the gluten challenge, participants were permitted to eat *ad libitum*, and a pooled urine sample was collected for 8 h. For studies that required a barley or rye enriched diet, pancakes prepared with approximately 1.5 cups of barley (Arrowhead Mills), rye (Bob's Red Mill), or wheat (Bob's Red Mill) flour were substituted for bagels prepared with wheat flour, and participants refrained from eating any wheat, rye, or barley products until the end of the 8 h urine collection. In later experiments, volunteers were not prescribed a gluten-free diet the day prior to the gluten challenge but were instructed to fast overnight. After fasting, participants collected a spot urine sample, and underwent the dietary gluten challenge as previously described. Subsequent to this gluten challenge, a pooled urine sample was collected for 8 h in a 4 L urine container (Simport Scientific #B3504L), whereas spot urine samples were collected in 120 mL urine collection cups (Thermo Scientific #010001). Urine was stored at 4 °C throughout the collection day and was preprocessed and frozen on the same day it was collected. To do so, urine samples were centrifuged in 50-mL polypropylene tubes for 3000 *x g* for 20 min and transferred to 15 mL polypropylene tubes in 10-15 mL aliquots. Samples were stored at -80 °C until further analysis.

Creatinine Normalization and Urinary Peptidome Enrichment. At the time of analysis, urine samples were placed in a 37 °C water bath until just thawed and then centrifuged at 5000 *x g* for 5 min at room temperature to pellet any precipitates. For all analyses, urine samples were processed in singlicate, except for the Clinical Study presented in **Fig. 5**, in which samples were processed in duplicate on two separate days. Creatinine levels were measured using a kit (Cayman Chemical #500701) according to the manufacturer protocol. Briefly, urine sample aliquots were diluted 1:10 in MilliQ water and 15 µL of the diluted samples, or 15 µL of the kit-provided creatinine standard (0-20 mg/dL final concentration, also diluted in water) were added to a 96-well plate followed by 150 µL of alkaline picrate solution. After incubation for 10 min at room temperature, the initial absorbances at 500 nm were determined on a plate reader. The reaction was quenched with 5 µL of the kit-provided acid solution, incubated for 20 minutes, and the final absorbances at 500 nm was measured. Final absorbance values were subtracted from the initial values, and a calibration curve using the creatinine standards was constructed. The creatinine concentrations from the urine samples were calculated based on this curve. If a urine sample reading fell out of the linear range, the measurement was repeated using an appropriate dilution. Then, a volume of urine containing *ca*. 30 µmol creatinine (1-10 mL for most donors) was neutralized by addition of aqueous 1 M ammonium bicarbonate solution to a final concentration of 50 mM. Samples were reduced for 30 min at room temperature by dithiothreitol (500 mM aqueous stock added to a final concentration of 2 mM) and then alkylated in the dark with iodoacetamide (500 mM aqueous stock added to a final concentration of 4 mM) for 30 min at room temperature. Urine was acidified with mass spectrometry-grade formic acid to a final concentration of 2% (v/v). To enrich the low-molecular weight urinary peptidome, the acidified samples were applied to water-washed Vivaspin Centrifugal Filtration Columns (Sartorius, #VS0602) with a molecular weight cutoff of 10 kDa, and centrifuged at 4000 *x g* until less than 200 µL urine remained in the retentate. The filtrate was then processed by solid phase extraction, as described below.

Solid Phase Extraction of Urinary Peptides. To remove salts, metabolites, and urinary pigments that interfere with downstream LC-MS/MS analysis, solid phase extraction of peptidome-enriched urine was performed using Oasis Mixed Cation Exchange Prime Columns (3 cc size, 100 mg resin, Waters Corporation #186008918). The filtrate from the prior centrifugal filtration step was applied at a rate of approximately 2 drops/s. The column was washed with 1 mL of an aqueous solution of 2% formic acid containing 100 mM ammonium formate, followed by 1 mL methanol. The resin was re-equilibrated with 2 mL aqueous 2% formic acid, then washed with 1 mL 95% water/5% ammonium hydroxide followed by 1 mL 95% acetonitrile/5% ammonium hydroxide. The reequilibriation and wash steps were repeated one additional time. Peptides were eluted in 1 mL 95% methanol/5% ammonium hydroxide directly into a low-binding microcentrifuge tube (Fisher #3453) at a rate of approximately 1 drop every 2 seconds and dried using vacuum centrifugation. Dried peptides were stored at 4 °C.

LC-MS/MS Analysis. At the time of analysis, solid phase extracted urine samples were reconstituted in 25 µL MilliQ water. The resuspended peptides were centrifuged at 16,300 x g for 10 min, and the supernatants were transferred to low-binding ultra-performance liquid chromatography vials (Wheaton #11-0000-100-S) and analyzed on a Fusion Lumos mass spectrometer (Thermo Fisher Scientific, San Jose, USA). Peptides were separated by capillary reverse phase chromatography on a 24 cm reversed phase column (100 µm inner diameter, packed in-house with ReproSil-Pur C18-AQ 3.0 µm resin from Dr. Maisch GmbH). The Fusion Lumos was equipped with a Dionex Ultimate 3000 LC system and used a two-step linear gradient with 4–25 % buffer B (0.1% (v/v) formic acid in acetonitrile) for 50 min followed by 25-50% buffer B for 20 min, where buffer A was 0.1% (v/v) formic acid in water. Sample analysis with the Fusion Lumos system (Tune 3.3) was carried out in top speed data dependent mode

with a duty cycle time of 3 s. Full MS scans were acquired in the Orbitrap mass analyzer with a resolution of 120 000 (FWHM) and m/z scan range of 400-1500. Precursor ions with charge state 2-7 and intensity threshold above 50,000 were selected for fragmentation using collision-induced dissociation (CID) with quadrupole isolation, isolation window of 1.6 m/z, normalized collision energy of 35%, activation time of 10 ms and activation Q of 0.25. Precursor ions with charge state 3-7 were also selected for fragmentation using electron transfer dissociation (ETD) supplemented with 25% collision energy (EThcD). Calibrated charge dependent ETD parameters were enabled. MS2 fragment ions were analyzed in the Orbitrap mass analyzer with a resolution of 15,000 (FWHM) and m/z scan range of 156-2000. Fragmented precursor ions were dynamically excluded from further selection for a period of 30 seconds. The AGC target was set to 400,000 and 50,000 for full FTMS scans and FTMS2 scans. The maximum injection time was set to “auto” for full FTMS scans and to “dynamic” for FTMS2 scans.

Data Analysis. To identify peptides originating from the human and wheat proteomes, and in some cases, the barley and rye proteomes, the corresponding protein sequences were downloaded from UniProt (www.uniprot.org) to generate custom FASTA databases, as detailed in the **Supplementary Methods.** The raw MS data were searched against these databases using PEAKS software (versions X or X+, Bioinformatics Solutions, Inc.). Carbamidomethylation (on Cys) was set as a fixed modification and deamidation (on Asn and Gln), oxidation (on Met), and N-terminal pyroglutamination (on Gln and Glu) were allowed as variable modifications, with a maximum of 3 variable modifications per peptide. The allowed mass tolerances were 10 ppm for precursor ions and 0.02 Da for product ions. The digest mode was “unspecific”. Peptides identified in each urine sample were filtered to a false discovery rate of 1% using the decoy-fusion approach implemented in PEAKS. Sequences were assigned to the human and wheat proteomes, and wheat peptide assignments were manually validated to ensure correct assignment of deamidation, as detailed in the **Supplementary Methods.**

DATA AVAILABILITY

The mass spectrometry data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (https://www.ebi.ac.uk/pride/) with the dataset identifier PXD023160. Source data are provided with the paper.

ACKNOWLEDGMENTS

We thank Elvi Sanjines and Gotzone Garay for support with patient recruitment, and Dr. Carlos Gonzales, Dr. Niclas Olsson, and Shelley Dutt for assistance with mass spectrometry. We also thank Dr. Emma Chory for helpful discussions on data processing and visualization. Parts of some figures in this manuscript were created using BioRender.com.

C.K. and B.J received support for this research from the National Institutes of Health under award number NIH R01 DK063158. C.K. gratefully acknowledges seed funding from The Joint Institute for Metrology in Biology, founded by the National Institute of Standards and Technology. J.E.E. is supported by the Chan Zuckerberg Biohub. N.F.B. gratefully acknowledges Joelle and Robert Triebsch and the Division of Gastroenterology and Hepatology for supporting our celiac translational research program. C.S. was supported by a grant from Ministerio de Ciencia e Innovación from Spain and FEDER funds (SAF2017-83700-R).

AUTHOR CONTRIBUTIONS

B.A.P., N.W., L.Z., A.J.H., B.J., N.Q.F., C.K., and J.E.E. designed research. B.A.P., N.W., L.Z., A.J.H., L.A.F., and K.S. performed research. C.S. contributed reagents and specimens. B.A.P.,

573 N.W., L.Z., A.J.H., C.K., and J.E.E. analyzed the data. B.A.P., N.W., A.J.H., C.K., and J.E.E.
574 wrote the paper with input from all authors.
575



Fig 1. An efficient chemical extraction and LC-MS/MS workflow for urinary peptidomic analysis. Urine sample volumes are first normalized based on creatinine measurement. To prevent the formation of intra- or intermolecular disulfide bonds that would confound downstream data analysis, cysteine (Cys) residues are reduced with dithiothreitol (DTT) and alkylated with iodoacetamide (IAM). Proteins are depleted using a centrifugal filtration device with a molecular weight cutoff (MWCO) of 10 kDa under acidic denaturing conditions. The filtrate is processed using a mixed cation exchange solid phase extraction column to remove metabolites and salts that interfere with LC-MS/MS analysis. After extensive washing, peptides are eluted from the column with methanol containing 5% ammonium hydroxide. Eluted peptides are dried in a centrifugal vacuum concentrator and reconstituted in water. Peptides are separated by nano-liquid chromatography (LC) on a reversed-phase column (RP-C18) and analyzed by tandem mass spectrometry (MS/MS) on an Orbitrap Fusion mass spectrometer operated in the data dependent acquisition (DDA) mode, with precursor and fragment ions analyzed in high resolution in the Orbitrap (OT). The resulting LC-MS/MS data are searched against the desired databases (e.g., the human and wheat proteomes). The experimental workflow takes ~6 h to complete and results in the identification of thousands of peptides.



e

Wheat Peptide Sequence	Uniprot Protein Accession(s)	Protein Name(s)	Mass (Da)	# of Participants with Peptide
GQQQPFPPQQPYPQPQPFPS	GDA0_WHEAT; GDA1_WHEAT; GDA2_WHEAT; GDA9_WHEAT	α/β-gliadin	2292.0962	8
GQQQPFPPQQPYPQPQPFP	GDA0_WHEAT; GDA1_WHEAT; GDA2_WHEAT; GDA9_WHEAT	α/β-gliadin	2205.0642	7
SQQPEQTIS**QQPQQPFPQ**QPHQPQQPYPQQQPYGSSL	A0A290XYU3_WHEAT; U5UA46_WHEAT; R9XT67_WHEAT; R9XUY1_WHEAT	ω-gliadin	4284.0259	6
SCHVMQQQCCQ	GDB1_WHEAT; GLTC_WHEAT; GDB3_WHEAT; GLTB_WHEAT	γ-gliadin; LMW glutenin	1464.5370	6
LGQQQPFPPQQPYPQPQPFPSQQP	GDA1_WHEAT; A0A0K2QJX_WHEAT; A0A0E3Z7F7_WHEAT; A0A1K0JNE4_WHEAT	α/β-gliadin; α-gliadin	2758.3500	5
S**QQPQQPFPQ**QPHQPQQPYPQ	B6ETR9_WHEAT; A0A290XYU3_WHEAT; U5UA46_WHEAT; R9XT67_WHEAT	ω-gliadin; LMW glutenin	2865.3582	5
SCHVMQQQCC	GDB1_WHEAT; GLTC_WHEAT; GDB3_WHEAT; GLTB_WHEAT	γ-gliadin; LMW glutenin	1352.4730	5
PyrQTFPHQPQQQVPQPQQPQQP	GDB2_WHEAT; B6DQB5_WHEAT; R9XWD0_WHEAT; R9XUB9_WHEAT	γ-gliadin	2348.1296	4
PQQPPFSQQQQQQQQQQQP**PFSQQQQPV**L	Q5MFQ2_WHEAT; D0EVP4_WHEAT; Q5MFQ1_WHEAT; Q5MFQ6_WHEAT	LMW glutenin	1153.5658	3
TQQPQQPFPQQPQQPFPQQPQQPFPQ	R9XUS6_WHEAT; A0A290XZ20_WHEAT; A0A290XZ51_WHEAT; A0A290XZ34_WHEAT	γ-gliadin	3098.4998	3
T**QQPQQPFPQQPQ**QPFPQT**QQPQQPFPQ**	GDB2_WHEAT; B6DQB5_WHEAT, R9XV87_WHEAT; R9XWD0_WHEAT	γ-gliadin	3327.6060	3
QPFPPQQPYPQPQPFP	GDA0_WHEAT; GDA1_WHEAT; GDA2_WHEAT; GDA9_WHEAT	α/β-gliadin	1891.9257	2
PLQP**QQPFPQQPQQPFPQPQ**	B6ETR9_WHEAT; A0A290XYW6_WHEAT; R9XT67_WHEAT; R9XUY1_WHEAT	ω-gliadin	2354.1807	2
FLQP**QQPFPQQPQQPYPQQPQQPFPQ**	GDB0_WHEAT, R9XV78_WHEAT; Q9FS77_WHEAT, B6UKM8_WHEAT	γ-gliadin	3145.5410	1
CHVMQQQCCQ	GDB1_WHEAT; GLTC_WHEAT; GDB3_WHEAT; GLTB_WHEAT	γ-gliadin; LMW glutenin	1393.5000	1
PyrQQQQPPFSQQPPISQQQQPPFSQQQQPQF	GLTA_WHEAT, D2DII3_WHEAT, Q6SPZ1_WHEAT, Q6SPZ3_WHEAT	LMW glutenin	1139.879	1

595

Fig 2. LC-MS/MS enables the identification of chemically defined dietary wheat peptides in human urine. a Pilot study design. **b** Number of wheat-derived peptide sequences detected in the urine of 4 healthy participants after a 24-hour gluten-free diet and after a dietary challenge with wheat gluten. Horizontal line represents median. **c** Simplified study design. **d** Number of wheat-derived peptide sequences detected in 8 healthy participants after an overnight fast and after a dietary challenge with wheat gluten. Horizontal line represents median. **e** Examples of wheat-derived peptide sequences identified in human urine. Bolded residues indicate CeD-relevant T-cell epitopes, as defined in ref. [36]. Underlines indicate that Cys residues were detected in their carbamidomethylated forms due to derivatization with iodoacetamide during sample workup. "PyrQ" indicates glutamine residues that had undergone cyclization into pyroglutamic acid. For peptides mapping to more than four proteins in the UniProt database, only the first four accession codes are displayed. All identified peptide sequences and full details relating to peptide identification in each participants' urine is provided in **Supplementary Datasets 3 and 4**. In all LC-MS/MS experiments, peptide identifications were controlled at a false discovery rate of 1% using the PEAKS software decoy-fusion approach[57].



Fig 3. LC-MS/MS analysis of urine from two healthy volunteers challenged with dietary wheat, rye, and barley. a Illustration of sequence differences between closely related gliadin, secalin, and hordein proteins from wheat, rye, and barley, respectively. The boxes highlight source-specific sequence regions. **b** All possible intersections of the three sets of peptide sequences identified after the grain challenges are depicted as an UpSet plot[58]. The individual set size is plotted to the left of each row, with the grey portion of the bar representing sequences that map uniquely to the respective dietary challenge proteome, and the orange portion representing those that do not. There are no intersections between these sets of peptides, suggesting the peptides depicted in orange are nonetheless likely to have originated from the specific grain used for the dietary challenge. **c** Number of distinct peptide sequences uniquely mapping to the wheat, barley, and rye proteomes following dietary challenges. Sequences that mapped to more than one of the proteomes were excluded from this figure. Sequences that mapped to more than one of the proteomes were excluded from this figure. In the rye diet, sequences mapping uniquely to the wheat proteome were only found in the rye diet, suggesting they are yet unannotated rye peptides. A full list of observed peptide sequences and their respective proteome mappings is provided in **Supplementary Dataset 5**.



Fig 4. LC-MS/MS analysis of banked urine samples from patients with CeD[27]. Urine collected from a single void was tested for the presence of gluten by an A1 and G12 monoclonal antibody-based lateral flow assay. Each data point represents a single urine sample, and the horizontal bar indicates the median. Information associated with the identification of these peptide sequences by LC-MS/MS is provided in **Supplementary Dataset 6**.



d

Epitope Name(s)	Epitope Sequence	# Peptides with Epitopes CeD	GI	HC
DQ2.5-glia-α1a	PFPQPQLPY	2	0	0
DQ2.5-glia-α1b	PYPQPQLPY	1	0	0
DQ2.5-glia-α2	PQPQLPYPQ	2	0	0
DQ2.5-glia-α3	FRPQQPYPQ	1	0	0
DQ2.5-glia-γ1/DQ8.5-glia-γ1	PQQSFPQQQ	1	0	1
DQ2.5-glia-γ3/DQ8-glia-γ1b	QQPQQPYPQ	6	1	0
DQ2.5-glia-γ4a	SQPQQQFPQ	1	0	0
DQ2.5-glia-γ4b	PQPQQQFPQ	8	4	3
DQ2.5-glia-γ4c/DQ8-glia-γ1a	QQPQQPFPQ	105	29	36
DQ2.5-glia-γ4d	PQPQQPFCQ	2	0	1
DQ2.5-glia-γ4e	LQPQQPFPQ	28	5	4
DQ2.5-glia-γ5	QQPFPQQPQ	37	10	15
DQ2.5-glia-ω1/DQ2.5-hor-1/DQ2.5-sec-1	PFPQPQQPF	3	0	1
DQ2.5-glia-ω2	PQPQQPFPW	1	0	0
DQ2.5-glut-L1/DQ2.2-glut-L1	PFSQQQQPV	17	2	11
DQ2.5-glut-L2	FSQQQQSPF	1	0	0
DQ8.5-glut-H1/DQ8-glut-H1	QGYYPTSPQ	2	0	1
DQ8-glia-γ2	PQQSFPQQQ	1	0	1



f

Wheat Peptide Sequence	Protein Name	# of CeD Patients with Peptide
PQQQIPQQHQIPQQPQQFPQQ	ω-gliadin	5
GQQQQQFPGQQQPFPPQQPYPQPQP	α/β-gliadin	4
PELQQPIPQQPQQPFPLQPQQPFPQQ	ω-gliadin	4
PTSPQQSGQGQQPGQWQQPGQGQPG	HMW-glutenin	4



Fig 5. The urinary wheat peptidomes of patients with CeD are significantly more diverse than in healthy controls or patients with non-celiac gastrointestinal disorders. a Clinical

study design. Participants were recruited over approximately two years within the Celiac Disease Program at the Stanford Digestive Health Center. **b** Number of wheat peptides detected in pooled urine samples collected for 8 h subsequent to a dietary challenge with two bagels (~18 g gluten). Patients with CeD had substantially more wheat peptide sequences compared to healthy controls (p=0.017) or patients with non-celiac gastrointestinal disorders (p=0.017). **c** Number of unique wheat-derived peptide sequences with at least one T-cell epitope in patients with CeD compared to healthy controls (p=0.019) and patients with non-celiac gastrointestinal disorders (p=0.046). **b**,**c** One-way Kruskal-Wallis ANOVA/Dunn's multiple comparison test, horizontal bar represents the median. **d** Summary of detected T-cell epitopes. **e** Venn diagram comparing the unique peptide sequences detected in healthy controls, patients with CeD, and other GI patients. A full listing of peptide sequences is provided in **Supplementary Dataset 7**. **f** Wheat-derived peptide sequences detected in the majority of patients with CeD but not in control groups. **g** Schematic describing how the frequencies at which urinary wheat-derived peptides map to proteins in the wheat proteome were plotted as heatmaps. **h-j** Heatmap representation of detected peptide sequences in alpha/beta gliadin 2 (GDA2), γ-gliadin 2 (GDB2) and gamma-gliadin X (GDBX) demonstrates that while many peptides map to the same region of the wheat proteome, the urinary wheat peptidomes of patients with CeD also occupy distinct chemical space. Below the maps, the locations of CeD T-cell epitopes are highlighted in red, and the relative density of Gln and Pro is indicated in yellow. Heatmaps for other proteins in the wheat proteome are provided in **Supplementary Fig. 10.** In **b-h**, all samples were analyzed in duplicate the aggregated results are shown. Analyses of individual replicates are provided in Supplementary Fig. 11. Full details on LC-MS/MS identification of peptide sequences is provided in Supplementary Dataset 7.



Fig 6. Schematic representation of relevant metabolic products of dietary gluten in humans. Wheat-derived proteins such as gluten are resistant to gastrointestinal proteolysis. Incomplete digestion preserves disease-causing T-cell epitopes (depicted in red) in peptides that accumulate in the gut lumen. A portion of these gluten peptides translocate to the lamina propria where transglutaminase 2 (TG2) deamidates selected Gln residues (brown dots) in some sequences, thereby converting them into Glu residues (yellow dots). Absorbed peptides can also enter the blood stream, and are further metabolized and/or excreted into urine.

REFERENCES

1. Erickson, R. H. & Kim, Y. S. Digestion and absorption of dietary protein. *Annu. Rev. Med.* **41**, 133-139 (1990).
2. Miner-Williams, W. M., Stevens, B. R. & Moughan, P. J. Are intact peptides absorbed from the healthy gut in the adult human? *Nutr. Res. Rev* **27**, 308-329 (2014).
3. Shan, L. & Khosla, C. Chemistry and Biology of Gluten Proteins. *Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Immunology, Endocrine and Metabolic Agents)* **7**, 187-193 (2007).
4. Shan, L. et al. Structural basis for gluten intolerance in celiac sprue. *Science* **297**, 2275-2279 (2002).
5. Heyman, M., Abed, J., Lebreton, C. & Cerf-Bensussan, N. Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis. *Gut* **61**, 1355-1364 (2012).
6. Green, P. H. & Cellier, C. Celiac disease. *N. Engl. J. Med.* **357**, 1731-1743 (2007).
7. Leffler, D. A., Green, P. H. & Fasano, A. Extraintestinal manifestations of coeliac disease. *Nat. Rev. Gastroenterol. Hepato.l* **12**, 561-571 (2015).
8. Plugis, N. M. & Khosla, C. Therapeutic approaches for celiac disease. *Best. Pract. Res. Clin. Gastroenterol.* **29**, 503-521 (2015).
9. Molberg, O. et al. Gliadin specific, HLA DQ2-restricted T cells are commonly found in small intestinal biopsies from coeliac disease patients, but not from controls. *Scand. J. Immunol* **46**, 103-109 (1997).
10. Sjöström, H. et al. Identification of a gliadin T-cell epitope in coeliac disease: general importance of gliadin deamidation for intestinal T-cell recognition. *Scand. J. Immunol.* **48**, 111-115 (1998).
11. van de Wal, Y. et al. Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin. *Proc. Natl. Acad. Sci USA* **95**, 10050-10054 (1998).
12. Arentz-Hansen, H. et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. *J. Exp. Med.* **191**, 603-612 (2000).
13. Iversen, R. et al. Efficient T cell-B cell collaboration guides autoantibody epitope bias and onset of celiac disease. *Proc. Natl. Acad. Sci. USA* **116**, 15134-15139 (2019).
14. Høydahl, L. S. et al. Plasma cells are the most abundant gluten peptide MHC-expressing cells in inflamed intestinal tissues from patients with celiac disease. *Gastroenterology* **156**, 1428-1439.e10 (2019).
15. de Ritis, G. et al. In vitro (organ culture) studies of the toxicity of specific A-gliadin peptides in celiac disease. *Gastroenterology* **94**, 41-49 (1988).
16. Shidrawi, R. G. et al. In vitro toxicity of gluten peptides in coeliac disease assessed by organ culture. *Scand J Gastroenterol* **30**, 758-763 (1995).
17. Maiuri, L. et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. *The Lancet* **362**, 30-37 (2003).
18. Meresse, B. et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. *Immunity* **21**, 357-366 (2004).
19. Hüe, S. et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. *Immunity* **21**, 367-377 (2004).
20. Nanayakkara, M. et al. P31-43, an undigested gliadin peptide, mimics and enhances the innate immune response to viruses and interferes with endocytic trafficking: a role in celiac disease. *Sci. Rep.* **8**, 10821 (2018).

21. Gómez Castro, M. F. et al. p31-43 Gliadin peptide forms oligomers and induces NLRP3 inflammasome/caspase 1- dependent mucosal damage in small intestine. *Front Immunol.* **10**, 31 (2019).
22. Qiao, S.-W. et al. Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule in celiac disease: importance of proline spacing and glutamine Deamidation. *J. Immunol.* **175**, 254-261 (2005).
23. Qiao, S. W., Sollid, L. M. & Blumberg, R. S. Antigen presentation in celiac disease. *Curr. Opin. Immuno.l* **21**, 111-117 (2009).
24. Dahal-Koirala, S. et al. Discriminative T-cell receptor recognition of highly homologous HLA-DQ2-bound gluten epitopes. *J. Biol. Chem.* **294**, 941-952 (2019).
25. Reichelt, W. H., Ek, J., Stensrud, M. & Reichelt, K. L. Peptide excretion in celiac disease. *J. Pediatr. Gastroenterol. Nutr.* **26**, 305-309 (1998).
26. Soler, M., Estevez, M. C., Moreno, M. L., Cebolla, A. & Lechuga, L. M. Label-free SPR detection of gluten peptides in urine for non-invasive celiac disease follow-up. *Biosens. Bioelectron.* **79**, 158-164 (2016).
27. Moreno, M. L. et al. Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing. *Gut* **66**, 250-257 (2017).
28. Costa, A. F. et al. Gluten immunogenic peptide excretion detects dietary transgressions in treated celiac disease patients. *World J. Gastroenterol.* **25**, 1409-1420 (2019).
29. Ruiz-Carnicer, Á. et al. Negative predictive value of the repeated absence of gluten immunogenic peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-up in celiac disease. *Am. J. Clin. Nutr.* **112,** 1240–1251 (2020).
30. Diaz-Amigo, C. & Popping, B. Accuracy of ELISA detection methods for gluten and reference materials: a realistic assessment. *J. Agric. Food. Chem.* **61**, 5681-5688 (2013).
31. Ráki, M. et al. Similar responses of intestinal T cells from untreated children and adults with celiac disease to deamidated gluten epitopes. *Gastroenterology* **153**, 787-798.e4 (2017).
32. Sigdel, T. K. et al. Optimization for peptide sample preparation for urine peptidomics. *Clin. Proteomics* **11**, 7 (2014).
33. Smith, C. R. et al. Deciphering the peptidome of urine from ovarian cancer patients and healthy controls. *Clin. Proteomics* **11**, 23 (2014).
34. Osman, A. A. et al. A monoclonal antibody that recognizes a potential coeliac-toxic repetitive pentapeptide epitope in gliadins. *Eur J Gastroenterol Hepatol* **13**, 1189-1193 (2001).
35. Morón, B. et al. Toward the assessment of food toxicity for celiac patients: characterization of monoclonal antibodies to a main immunogenic gluten peptide. *PLoS One* **3**, e2294 (2008).
36. Sollid, L. M. et al. Update 2020: nomenclature and listing of celiac disease-relevant gluten epitopes recognized by $CD4^+$ T cells. *Immunogenetics* **72**, 85-88 (2020).
37. Shan, L. et al. Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue. *J. Proteome Res.* **4**, 1732-1741 (2005).
38. Gazme, B., Boachie, R. T., Tsopmo, A. & Udenigwe, C. C. Occurrence, properties and biological significance of pyroglutamyl peptides derived from different food sources. *Food Sci. Hum. Wellness* **8**, 268-274 (2019).
39. Sato, K. et al. Occurrence of indigestible pyroglutamyl peptides in an enzymatic hydrolysate of wheat gluten prepared on an industrial scale. *J. Agric. Food Chem.* **46**, 3403-3405 (1998).
40. Van Coillie, E. et al. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. *Biochemistry* **37**, 12672-12680 (1998).

41. Biesiekierski, J. R. What is gluten? *J Gastroenterol. Hepatol.* **32**, 78-81 (2017).
42. Aebersold, R. & Mann, M. Mass-spectrometric exploration of proteome structure and function. *Nature* **537**, 347-355 (2016).
43. Di Meo, A. et al. An integrated proteomic and peptidomic assessment of the normal human urinome. *Clin. Chem. Lab. Med.* **55**, 237-247 (2017).
44. Van, J. A. D. et al. Peptidomic analysis of urine from youths with early type 1 diabetes reveals novel bioactivity of uromodulin peptides in vitro. *Mol. Cell. Proteomics* **19**, 501-517 (2020).
45. Arrieta, M. C., Bistritz, L. & Meddings, J. B. Alterations in intestinal permeability. *Gut* **55**, 1512-1520 (2006).
46. Kumar, S. et al. Abnormal small intestinal permeability in patients with idiopathic malabsorption in tropics (tropical sprue) does not change even after successful treatment. *Dig. Dis. Sci.* **56**, 161-169 (2011).
47. Lerner, A. & Matthias, T. Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. *Autoimmun. Rev.* **14**, 479-489 (2015).
48. Lerner, A. & Matthias, T. Processed food additive microbial transglutaminase and its cross-linked gliadin complexes are potential public health concerns in celiac disease. *Int. J. Mol. Sci.* **21**, (2020).
49. Silvester, J. A. et al. Most patients with celiac disease on gluten-free diets consume measurable amounts of gluten. *Gastroenterology* **158**, 1497-1499.e1 (2020).
50. Rubio-Tapia, A. et al. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. *Am. J. Gastroenterol.* **105**, 1412-1420 (2010).
51. Abadie, V. & Jabri, B. IL-15: a central regulator of celiac disease immunopathology. *Immunological Rev.* **260**, 221-234 (2014).
52. Abadie, V. et al. IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease. *Nature* **578**, 600-604 (2020).
53. Walther, B. et al. GutSelf: Interindividual Variability in the Processing of Dietary Compounds by the Human Gastrointestinal Tract. *Mol. Nutr. Food Res.* **63**, e1900677 (2019).
54. Parzanese, I. et al. Celiac disease: from pathophysiology to treatment. *World J. Gastrointest. Pathophysiol.* **8**, 27-38 (2017).
55. Vitorino, R. Digging deep into peptidomics applied to body fluids. *Proteomics* **18**, 1700401 (2018).
56. Rubio-Tapia, A. et al. ACG clinical guidelines: diagnosis and management of celiac disease. *Am. J. Gastroenterol.* **108**, 656-76 (2013).
57. Zhang, J. et al. PEAKS DB: de novo sequencing assisted database search for sensitive and accurate peptide identification. *Mol. Cell. Proteomics* **11**, M111.010587 (2012).
58. Lex, A., Gehlenborg, N., Strobelt, H., Vuillemot, R. & Pfister, H. UpSet: Visualization of intersecting sets. *IEEE Trans. Vis. Comput. Graph* **20**, 1983-1992 (2014).